CLIMARA (estradiol) by Bayer is estrogen receptor agonists [moa]. Approved for estrogen [epc]. First approved in 1994.
Drug data last refreshed 6h ago · AI intelligence enriched 9h ago
CLIMARA is a transdermal extended-release film formulation of estradiol, an estrogen receptor agonist approved in 1994 for hormone replacement therapy in menopausal women. It delivers estradiol through the skin to alleviate vasomotor symptoms, vaginal atrophy, and other menopausal manifestations. The mechanism works by binding estrogen receptors to restore hormonal balance in post-menopausal patients.
Brand is in defensive phase with modest Part D penetration; teams focus on retention and generic transition planning rather than growth initiatives.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on CLIMARA at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CLIMARA offers exposure to mature product management and defensive commercial strategy in a crowded, consolidating category. Roles emphasize payer relations, generic transition planning, and operational efficiency rather than innovation—suitable for professionals seeking stability but limited growth upside.